Xbrane announces that members of Xbrane’s management team have sold shares for tax purposes.

Corporate Information

English

News

Other Corporate Information

Xbrane Biopharma AB (publ) (“Xbrane” or “the Company”) (Nasdaq Stockholm: XBRANE) announces that members of Xbranes management team have sold shares to pay tax in relation to the allotment of shares in 2022, as part of a share savings program. The sale was necessary from the individuals private economy perspective. Siavash Bashiri has sold 14 852 shares and has a remaining ownership of 105 862. David Vikström sold 17 165 and has 30 153 shares after the sale.

"The sale is made solely for tax purposes and was necessary from a personal financial perspective. Siavash and David's remaining holdings in Xbrane are still by far their largest private financial investments. Their and the other management's commitment to Xbrane’s future remains," says Martin Åmark, CEO Xbrane.

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 53 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during the first quarter 2023. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com